Victory Capital Management Inc. Raises Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Victory Capital Management Inc. lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 34.4% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,609,728 shares of the medical equipment provider's stock after purchasing an additional 1,692,177 shares during the period. Victory Capital Management Inc. owned approximately 2.95% of Hologic worth $408,283,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in HOLX. Norges Bank acquired a new stake in Hologic in the fourth quarter valued at $133,414,000. Boston Partners boosted its holdings in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after buying an additional 1,602,463 shares in the last quarter. Champlain Investment Partners LLC acquired a new position in shares of Hologic in the 4th quarter valued at $79,291,000. Redwood Wealth Management Group LLC purchased a new position in shares of Hologic in the 1st quarter valued at $3,534,000. Finally, Northern Trust Corp raised its stake in Hologic by 26.9% during the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after acquiring an additional 668,086 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Performance

NASDAQ:HOLX traded up $0.21 during midday trading on Thursday, reaching $64.07. The stock had a trading volume of 917,483 shares, compared to its average volume of 2,383,116. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The stock has a market cap of $14.28 billion, a P/E ratio of 27.01, a P/E/G ratio of 2.32 and a beta of 0.55. The firm has a fifty day simple moving average of $62.16 and a two-hundred day simple moving average of $63.36. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. During the same quarter last year, the business earned $1.03 EPS. The business's revenue was down 1.2% on a year-over-year basis. On average, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Activity

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the purchase, the director directly owned 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

HOLX has been the subject of several research analyst reports. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and boosted their target price for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Royal Bank Of Canada dropped their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Evercore ISI boosted their price objective on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Finally, Stephens decreased their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $77.33.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.